Rula Abbud-Antaki, Ph.D., (also known as: Rula Abbud)
President and Chief Scientific Officer, Falcon Genomics, Inc. Dr. Rula Abbud-Antaki is a scientific entrepreneur whose vision is to facilitate the rapid translation of basic science breakthroughs into the clinical setting. As a co-founder, President, and CSO at Falcon Genomics, Inc., she has focused on translating genomic data into personalized and targeted therapy for breast cancer. She has developed two genomic tests: the Cancer BioChip System and the Falcon Breast Cancer Test. She holds several issued (US7,537,913, US8,110,375, CA2,593,494), and pending (US13,292,221, US13,441,855, PCT/US12/32664) patents for several inventions, including a kit and a method for screening inhibitors of three-dimensional (3D) tumor cell growth (the Cancer BioChip System), and systems and methods for individualized functional genomic profiling. Prior to her work at Falcon Genomics, she was a Research Scientist and Adjunct Assistant Professor at Cedars Sinai Medical Center and UCLA where she has studied mouse models of cancer and the role of cytokines. She was also Research Associate and Postdoctoral Fellow at Case Western Reserve University Department of Pharmacology, and she received her Ph.D. from the University of Pittsburgh Department of Physiology. She is dedicated at finding a cure for breast cancer. She has published her work in peer-reviewed journals and given presentations at scientific meetings to promote awareness for the need to bring genomic testing into the clinical setting.